A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor

Paul A Foster; Surinder K Chander; Simon P Newman; L W Lawrence Woo; Oliver B Sutcliffe; Christian Bubert; Dujin Zhou; Shiuan Chen; Barry V L Potter; Michael J Reed; Atul Purohit

doi:10.1158/1078-0432.CCR-08-1027

A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor

Paul A Foster
, Surinder K Chander
, Simon P Newman
, L W Lawrence Woo
, Oliver B Sutcliffe
, Christian Bubert
, Dujin Zhou
, Shiuan Chen
, Barry V L Potter
, Michael J Reed
, Atul Purohit

Research output: Contribution to journal › Article › peer-review

34 Citations (Scopus)

Abstract

The production of E2 is paramount for the growth of estrogen receptor-positive breast cancer. Various strategies have been used, including the use of enzyme inhibitors against either aromatase (AROM) or steroid sulfatase (STS), in an attempt to ablate E2 levels. Both these enzymes play a critical role in the formation of estrogenic steroids and their inhibitors are now showing success in the clinic.

Original language	English
Pages (from-to)	6469-77
Number of pages	9
Journal	Clinical Cancer Research
Volume	14
Issue number	20
DOIs	https://doi.org/10.1158/1078-0432.CCR-08-1027
Publication status	Published - 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1158/1078-0432.CCR-08-1027

Cite this

Foster, P. A., Chander, S. K., Newman, S. P., Woo, L. W. L., Sutcliffe, O. B., Bubert, C., Zhou, D., Chen, S., Potter, B. V. L., Reed, M. J., & Purohit, A. (2008). A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor. Clinical Cancer Research, 14(20), 6469-77. https://doi.org/10.1158/1078-0432.CCR-08-1027

@article{c7ef225d51fb418cb3a1550593433dd0,

title = "A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor",

abstract = "The production of E2 is paramount for the growth of estrogen receptor-positive breast cancer. Various strategies have been used, including the use of enzyme inhibitors against either aromatase (AROM) or steroid sulfatase (STS), in an attempt to ablate E2 levels. Both these enzymes play a critical role in the formation of estrogenic steroids and their inhibitors are now showing success in the clinic.",

author = "Foster, \{Paul A\} and Chander, \{Surinder K\} and Newman, \{Simon P\} and Woo, \{L W Lawrence\} and Sutcliffe, \{Oliver B\} and Christian Bubert and Dujin Zhou and Shiuan Chen and Potter, \{Barry V L\} and Reed, \{Michael J\} and Atul Purohit",

year = "2008",

doi = "10.1158/1078-0432.CCR-08-1027",

language = "English",

volume = "14",

pages = "6469--77",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research",

number = "20",

}

Foster, PA, Chander, SK, Newman, SP, Woo, LWL, Sutcliffe, OB, Bubert, C, Zhou, D, Chen, S, Potter, BVL, Reed, MJ & Purohit, A 2008, 'A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor', Clinical Cancer Research, vol. 14, no. 20, pp. 6469-77. https://doi.org/10.1158/1078-0432.CCR-08-1027

TY - JOUR

T1 - A new therapeutic strategy against hormone-dependent breast cancer

T2 - the preclinical development of a dual aromatase and sulfatase inhibitor

AU - Foster, Paul A

AU - Chander, Surinder K

AU - Newman, Simon P

AU - Woo, L W Lawrence

AU - Sutcliffe, Oliver B

AU - Bubert, Christian

AU - Zhou, Dujin

AU - Chen, Shiuan

AU - Potter, Barry V L

AU - Reed, Michael J

AU - Purohit, Atul

PY - 2008

Y1 - 2008

N2 - The production of E2 is paramount for the growth of estrogen receptor-positive breast cancer. Various strategies have been used, including the use of enzyme inhibitors against either aromatase (AROM) or steroid sulfatase (STS), in an attempt to ablate E2 levels. Both these enzymes play a critical role in the formation of estrogenic steroids and their inhibitors are now showing success in the clinic.

AB - The production of E2 is paramount for the growth of estrogen receptor-positive breast cancer. Various strategies have been used, including the use of enzyme inhibitors against either aromatase (AROM) or steroid sulfatase (STS), in an attempt to ablate E2 levels. Both these enzymes play a critical role in the formation of estrogenic steroids and their inhibitors are now showing success in the clinic.

U2 - 10.1158/1078-0432.CCR-08-1027

DO - 10.1158/1078-0432.CCR-08-1027

M3 - Article

C2 - 18927286

SN - 1078-0432

VL - 14

SP - 6469

EP - 6477

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 20

ER -

A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this